Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Daniel John Gooding | Executive Director | 30k | -- | 1973 |
| Dr. Joanne M. Holland | Consultant | -- | -- | 1975 |
| Mr. Benjamin Harber | Company Secretary | -- | -- | -- |
Nuformix plc
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 3
Description
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Corporate Governance
Upcoming Events
June 16, 2025 at 7:30 AM UTC - June 20, 2025 at 7:30 AM UTC
Nuformix plc Earnings Date
Recent Events
Recent Events Information Not Available